Alnylam Presents New Clinical, Real-World Data From Cardiovascular Portfolio At ACC.26, Reinforcing Potential Of RNAi To Deliver Fundamentally Differentiated, Effective, And Durable Impact Fo
− Vutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects Comparable to Patients More than Ten Years Younger –− Findings
03/30/2026